3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 1
3
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Dermatologic
1
Conditions
Melanoma
45
Carcinoma, Renal Cell
19
Neoplasm Metastasis
16
Leukemia, Myeloid, Acute
15
Kidney Neoplasms
14
Skin Neoplasms
11
Neoplasms
10
Leukemia
7
Breast Neoplasms
7
Lymphoma, Non-Hodgkin
6
Myelodysplastic Syndromes
5
Ovarian Neoplasms
4
Neuroblastoma
4
Congenital Abnormalities
4
Colorectal Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Hodgkin Disease
3
Uveal Melanoma
2
Prostatic Neoplasms
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Myeloid
1
Sarcoma, Ewing
1
Sarcoma
1
Interventions
Cisplatin
68
Paclitaxel
32
Radiotherapy
31
Carboplatin
23
Bevacizumab
21
pembrolizumab
20
Brachytherapy
18
atezolizumab
11
camrelizumab
10
Nivolumab
10
Gemcitabine
10
Drug Therapy
9
tislelizumab
8
Topotecan
8
Taxes
8
Chemoradiotherapy
8
Radiation
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
zimberelimab
6
toripalimab
6
nimotuzumab
6
Magnetic Resonance Spectroscopy
6
Cetuximab
6
lenvatinib
5
durvalumab
5
dostarlimab
5
Platinum
5
Papillomavirus Vaccines
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Uterine Cervical Neoplasms
×
Interleukin-2
×
Clear all
NCT06630611
2025-01-28
PragmaTIL
Vall d'Hebron Institute of Oncology
Phase 2
Recruiting
40 enrolled